PierianDx, a St. Louis, Missouri-based genomic software provider, raised $9.25m in Series A funding.
The round was led by Health Catalyst Capital Management, with participation from a venture investing affiliate of Ocean Road Advisors, Inova Translational Medicine Institute (ITMI), and ARUP Laboratories.
The company intends to use the funds to to accelerate product development and expand sales, marketing and operations efforts.
Led by CEO Ted Briscoe, PierianDx provides genomic software and services to enable data-driven personalized medicine. Its genomics software platform, Clinical Genomicist Workstation (CGW), provides data-driven workflow for health systems, academic medical centers, and commercial labs to improve patient outcomes through precise genomic analysis, interpretation and reporting.
FinSMEs
07/01/2016